Speaking as someone who was hoping that advanced biotech could provide an escape route from the looming disasters and potentially provide 'uplift' strategies, I'm having something of a crisis of faith in the technocratic institutions that I would previously have regarded as rock-solid.
Private-sector biotechnology, for instance. It recently emerged that billions of dollars worth of research into alzheimer's treatments have turned out to be based on an obviously fraudulent paper. This is a research domain where everyone concerned should, in principle, have had every opportunity and incentive to be critical in their evaluation of the evidence, and yet... they coasted on for years based on a falsehood that even a modicum of peer review could have dispelled.
Another redpill on biotech came when I found pharma spends more on marketing than R&D. They're not the future.
Private-sector biotechnology, for instance. It recently emerged that billions of dollars worth of research into alzheimer's treatments have turned out to be based on an obviously fraudulent paper. This is a research domain where everyone concerned should, in principle, have had every opportunity and incentive to be critical in their evaluation of the evidence, and yet... they coasted on for years based on a falsehood that even a modicum of peer review could have dispelled.
Two decades of Alzheimer's research may be based on deliberate fraud that has cost millions of lives
Last month, drug company Genentech reported on the first clinical trials of the drug crenezumab, a drug targeting amyloid proteins that form sticky plaques in the brains of Alzheimer’s disease patients. The drug had been particularly effective in...
www.dailykos.com
Another redpill on biotech came when I found pharma spends more on marketing than R&D. They're not the future.
